retatrutide phase 3 triumph Achieves Up to 30.3% Average Weight Loss in TRIUMPH-1 Trial Retatrutide Shows 28.3% Weight Loss

Our practitioner was knowledgeable and patient with all our questions

As some patients may perceive their medications as only those in pill form or to deal with an illness, they may fail to include their regular use of GLP-1 agonists as part of their history

Every weight loss journey is personal, and finding the right balance can be challenging

As consumer expectations evolve and new therapies emerge, providers must confront a challenging question: What happens if and when surgery is no longer the default standard of care

It was not a major reason for discontinuation in the trial, but it represents a side effect category that tirzepatide users do not encounter